Domain Therapeutics is a French-based biotech company developing small molecules therapeutics targeting immune-oncology, CNS or rare diseases. We are looking for motivated and talented postdoctoral researchers to co-apply for a European grant under the Marie Sklodowska-Curie Actions – Individual Fellowship 2020.

You will find all the information about these opportunities by following this link:
https://www.domaintherapeutics.com/about-us/domain-therapeutics-careers-join-us/

Position offered upon grant obtention:
•2 year postdoctoral position in a growing company.

Key deadlines are :
•Application before August 15th, 2020.
•Grant submission before September 9th, 2020.
•Estimated project start around March 1st, 2021.

Eligibility criteria:
•The researcher can be of any nationality.
•The researcher must hold a PhD by the grant submission deadline.
•The researcher must not have worked or lived in France for more than 12months in the past 3years.

To apply, follow the procedure provided for each project of your choice.
************

Open positions Domain Therapeutics is looking for post-doctoral researchers, to co-apply for a Marie Sklodowska-Curie Fellowship. The position will only be open upon obtention of the European grant. For a successful application, you have to fit the eligibility criteria requested by the European Union.
August 15, 2020 : deadline for candidate application at Domain Therapeutics
September 9, 2020 : deadline for the grant co-application
March 2021 : estimated starting date of the project

Implementation of a novel proprietary technology for in-vivo and in-vitro target and drugs validation (ref: MSCA-DT01) See the Offer

Development of biomarkers for target engagement and efficacy using an ex-vivo pharmacology approach (ref: MSCA-DT02) See the Offer

Characterization of tumour-infiltrated lymphocytes (TILs) and immunosuppressive myeloid cells (gMDSCs and mMDSCs) from human tumours (ref: MSCA-DT03) See the Offer

Characterization of therapeutic antibodies on human and mouse GPCRs (ref: MSCA-DT04) See the Offer

Development of novel BRET biosensors targeting immune-checkpoints (ref: MSCA-DT05) See the Offer

Novel animal models validation of chemotherapy-related neuropathies (ref: MSCA-DT06) See the Offer

Design and synthesis of a novel smart drug-like small molecule library. (ref: MSCA-DT07) See the Offer